Literature DB >> 21600382

Approved agents for metastatic breast cancer.

Monica N Fornier1.   

Abstract

The US Food and Drug Administration has approved three agents for treatment of patients with metastatic breast cancer refractory to anthracyclines and taxanes: capecitabine, ixabepilone, and eribulin mesylate. There is no fixed algorithm of therapeutic choices. Median survival remains measured in months, not years. Individual patient performance status, toxicity (to past regimens and any residual toxicity), preferences, and quality of life are factors in determining optimal treatment options for metastatic breast cancer. Ongoing research is seeking to improve outcomes in this patient population.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21600382     DOI： 10.1053/j.seminoncol.2011.04.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  9 in total

1.  Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization.

Authors:  Fang-Ke Huang; Shaoqin Han; Bowen Xing; Jianyun Huang; Bingqian Liu; Francois Bordeleau; Cynthia A Reinhart-King; J Jillian Zhang; Xin-Yun Huang
Journal:  Nat Commun       Date:  2015-06-17       Impact factor: 14.919

2.  Improving fascin inhibitors to block tumor cell migration and metastasis.

Authors:  Shaoqin Han; Jianyun Huang; Bingqian Liu; Bowen Xing; Francois Bordeleau; Cynthia A Reinhart-King; Wenxin Li; J Jillian Zhang; Xin-Yun Huang
Journal:  Mol Oncol       Date:  2016-04-01       Impact factor: 6.603

3.  Disordering of human telomeric G-quadruplex with novel antiproliferative anthrathiophenedione.

Authors:  Dmitry Kaluzhny; Nikolay Ilyinsky; Andrei Shchekotikhin; Yuri Sinkevich; Philipp O Tsvetkov; Vladimir Tsvetkov; Alexander Veselovsky; Mikhail Livshits; Olga Borisova; Alexander Shtil; Anna Shchyolkina
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

4.  Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.

Authors:  Yasuhiro Funahashi; Kiyoshi Okamoto; Yusuke Adachi; Taro Semba; Mai Uesugi; Yoichi Ozawa; Osamu Tohyama; Taisuke Uehara; Takayuki Kimura; Hideki Watanabe; Makoto Asano; Satoshi Kawano; Xavier Tizon; Paul J McCracken; Junji Matsui; Ken Aoshima; Kenichi Nomoto; Yoshiya Oda
Journal:  Cancer Sci       Date:  2014-09-16       Impact factor: 6.716

5.  Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Guanling Chen; Zhaoze Guo; Minfeng Liu; Guangyu Yao; Jianyu Dong; Jingyun Guo; Changsheng Ye
Journal:  Oncol Res       Date:  2017-03-23       Impact factor: 5.574

6.  Taxanes for the treatment of metastatic breast cancer.

Authors:  W J Gradishar
Journal:  Breast Cancer (Auckl)       Date:  2012-10-25

7.  Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy.

Authors:  Guo-Shiou Liao; Maria Karmella Apaya; Lie-Fen Shyur
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-12       Impact factor: 2.629

8.  Relationship between Chinese medicine dietary patterns and the incidence of breast cancer in Chinese women in Hong Kong: a retrospective cross-sectional survey.

Authors:  Xiao Zheng; Jianping Chen; Ting Xie; Zhiyu Xia; Wings Tjing Yung Loo; Lixing Lao; JieShu You; Jie Yang; Kamchuen Tsui; Feizhi Mo; Fei Gao
Journal:  Chin Med       Date:  2017-06-29       Impact factor: 5.455

9.  Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience.

Authors:  B J Srinivasa; Bhanu Prakash Lalkota; Girish Badarke; Diganta Hazarika; Nasiruddin Mohammad; Sulav Sapkota; Mansi Khanderia; D Tousif; Raghavendra Rao; Amritanshu Ram; Shekar Patil; Radheshyam Naik
Journal:  Clin Med Insights Oncol       Date:  2018-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.